Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about LIF: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
LIF is a gene implicated in neurodegeneration research. Key relationships include: activates, inhibits, therapeutic target. Associated with Autoimmune, Cancer, Carcinoma. Connected to 58 entities in the SciDEX knowledge graph.
No AI portrait yet
| Gene Symbol | LIF |
| Full Name | Leukemia Inhibitory Factor |
| Aliases | Page for LIF Receptor Protein |
| Chromosome | 5p13.1 |
| Function | The LIF gene encodes a 202-amino acid secreted glycoprotein that acts as a multifunctional cytokine: |
| Molecular Weight | 190 kDa |
| Amino Acids | 202 aa |
| Exons | 20 |
| Pathways | MAPK, PI3K |
| UniProt ID | P15018 |
| NCBI Gene ID | 3977 |
| Ensembl ID | ENSG00000128342 |
| OMIM | 159446 |
| GeneCards | LIF |
| Human Protein Atlas | LIF |
| Associated Diseases | multiple sclerosis |
| Interactions | Actin, AND, App, ASTROCYTE, ASTROCYTES, BDNF |
| KG Connections | 125 knowledge graph edges |
| Databases | GeneCardsHPASTRING |
Knowledge base pages for this entity
graph TD
LIF["LIF"]
LIFR["LIFR"]
LIF -->|"binds"| LIFR
neurite_damage(["neurite damage"])
LIF -->|"protects against"| neurite_damage
Cancer{"Cancer"}
LIF -->|"inhibits"| Cancer
Leukemia{"Leukemia"}
LIF -->|"inhibits"| Leukemia
Ms{"Ms"}
LIF -->|"activates"| Ms
Tumor{"Tumor"}
LIF -->|"activates"| Tumor
LIF -->|"activates"| Leukemia
Carcinoma{"Carcinoma"}
LIF -->|"activates"| Carcinoma
LIF -->|"activates"| Cancer
LIF -->|"therapeutic target"| Tumor
EGFR["EGFR"]
LIF -->|"activates"| EGFR
Epigenetic(["Epigenetic"])
LIF -->|"inhibits"| Epigenetic
JAK_STAT(["JAK-STAT"])
JAK_STAT -->|"activates"| LIF
EGFR -->|"activates"| LIF
GENES["GENES"]
GENES -->|"activates"| LIF
DNA["DNA"]
DNA -->|"activates"| LIF
STAT3["STAT3"]
STAT3 -->|"activates"| LIF
LIFR -->|"expressed in"| LIF
GFAP["GFAP"]
GFAP -->|"expressed in"| LIF
SOX2["SOX2"]
SOX2 -->|"activates"| LIF
LIFR -->|"activates"| LIF
AND["AND"]
AND -->|"inhibits"| LIF
CANCER["CANCER"]
CANCER -->|"inhibits"| LIF
HIPPO["HIPPO"]
HIPPO -->|"activates"| LIF
style LIF fill:#1a3a4a,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0| Target | Relation | Type | Str |
|---|---|---|---|
| Leukemia | activates | disease | 0.75 |
| Tumor | activates | disease | 0.75 |
| Cancer | activates | disease | 0.75 |
| CANCER | activates | gene | 0.70 |
| CYTOKINES | inhibits | gene | 0.70 |
| neurite damage | protects_against | process | 0.70 |
| Leukemia | inhibits | disease | 0.65 |
| Autoimmune | therapeutic_target | disease | 0.65 |
| Cancer | therapeutic_target | disease | 0.65 |
| Ms | activates | disease | 0.65 |
| Infection | therapeutic_target | disease | 0.65 |
| Multiple Sclerosis | activates | disease | 0.65 |
| Inflammation | therapeutic_target | disease | 0.65 |
| Cancer | inhibits | disease | 0.65 |
| Carcinoma | activates | disease | 0.65 |
| ALS | expressed_in | disease | 0.65 |
| Tumor | therapeutic_target | disease | 0.65 |
| Prostate Cancer | activates | disease | 0.65 |
| GEM | activates | gene | 0.60 |
| CAV1 | inhibits | gene | 0.60 |
| Egfr Signaling | activates | pathway | 0.60 |
| Hippo Pathway | activates | pathway | 0.60 |
| Epigenetic | activates | pathway | 0.60 |
| Tumor Microenvironment | activates | pathway | 0.60 |
| Differentiation | activates | pathway | 0.60 |
| Immune Checkpoint | activates | pathway | 0.60 |
| WNT | activates | gene | 0.60 |
| Actin | activates | protein | 0.60 |
| Myosin | activates | protein | 0.60 |
| Chemokine | activates | protein | 0.60 |
| Interleukin | inhibits | protein | 0.60 |
| Cytokine | inhibits | protein | 0.60 |
| Ubiquitin | inhibits | protein | 0.60 |
| HOPX | expressed_in | gene | 0.60 |
| Pericyte | therapeutic_target | cell_type | 0.60 |
| TGF-beta signaling | participates_in | pathway | 0.60 |
| JAK-STAT signaling | participates_in | pathway | 0.60 |
| ubiquitin-proteasome | participates_in | pathway | 0.60 |
| AND | activates | gene | 0.60 |
| SMAD3 | activates | gene | 0.60 |
| BRD4 | activates | gene | 0.60 |
| BDNF | activates | gene | 0.60 |
| LIFR | activates | gene | 0.60 |
| CNTF | inhibits | gene | 0.60 |
| AND | inhibits | gene | 0.60 |
| EP300 | activates | gene | 0.60 |
| multiple sclerosis | associated_with | disease | 0.60 |
| Wnt | activates | pathway | 0.60 |
| CANCER | inhibits | gene | 0.60 |
| HIPPO | activates | gene | 0.60 |
| Source | Relation | Type | Str |
|---|---|---|---|
| JAK-STAT | activates | pathway | 0.70 |
| LIFR | activates | gene | 0.60 |
| CAV1 | activates | gene | 0.60 |
| HEDGEHOG | activates | gene | 0.60 |
| SOX2 | activates | gene | 0.60 |
| GENES | activates | gene | 0.60 |
| DNA | activates | gene | 0.60 |
| JAK | activates | gene | 0.60 |
| WNT | activates | gene | 0.60 |
| IL-6 | inhibits | gene | 0.60 |
| STAT3 | activates | gene | 0.60 |
| LIFR | expressed_in | gene | 0.60 |
| GFAP | expressed_in | gene | 0.60 |
| UBIQUITIN | inhibits | gene | 0.60 |
| HDAC5 | activates | gene | 0.60 |
| INFLAMMATION | therapeutic_target | gene | 0.60 |
| CANCER | therapeutic_target | gene | 0.60 |
| FGF | activates | gene | 0.60 |
| EGFR | activates | gene | 0.60 |
| CNTF | inhibits | gene | 0.60 |
| GEM | activates | gene | 0.60 |
| CAV1 | inhibits | gene | 0.60 |
| RNA | activates | gene | 0.60 |
| TNF | activates | gene | 0.60 |
| CANCER | inhibits | gene | 0.60 |
| HIPPO | activates | gene | 0.60 |
| CYTOKINES | inhibits | gene | 0.60 |
| ASTROCYTE | activates | gene | 0.60 |
| CYTOKINES | activates | gene | 0.60 |
| IL-17 | activates | gene | 0.60 |
| ASTROCYTES | activates | gene | 0.60 |
| EGFR | co_expressed_with | gene | 0.50 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Single-cell RNA sequencing analysis of human atherosclerotic plaques | exploratory | Atherosclerosis | 0.900 | 0.00 | Human atherosclerotic plaque s | proposed | N/A |
| bEV isolation and LPS quantification from human samples | clinical | Alzheimer's disease | 0.800 | 0.00 | human patients | proposed | N/A |
| Sequential DFO + Sulforaphane Prevents Iron-Ferroptosis Cascade in Rat | in_vivo | post-cardiac-arrest neurodegen | 0.768 | 0.72 | Sprague-Dawley rat asphyxial c | abandoned | $48,000 |
| Proposed experiment from debate on Synaptic pruning by microglia in ea | falsification | Alzheimer's Disease | 0.400 | 0.50 | mouse | proposed | $200,000 |
| Proposed experiment from debate on Senolytics targeting p16/p21+ senes | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $80,000 |
| Biomechanical Impact Profiles and Chronic Traumatic Encephalopathy Phe | clinical | Neurodegeneration | 0.400 | 0.50 | in_silico | proposed | $180,000 |
| Mechanism: Why Does Amyloid Removal Only Slow Decline 27%? | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Experiment: Autoimmune Hypothesis Testing in AD | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated Neurotoxic | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| cGAS-STING Pathway Validation Study in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $7,100,000 |
| Microglial Aging and Immune Memory in Neurodegeneration — Training the | validation | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $2,960,000 |
| Microglial Contributions to Huntington's Disease Pathogenesis | validation | Neuroinflammation | 0.400 | 0.50 | human | proposed | $2,960,000 |
| Mixed Pathology Effects on Parkinson's Disease Progression and Treatme | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Complement, Inflammasome, and Microglial Crosstalk in Glaucoma: From Neurodegene [PMID:41900887] | Chen TY, Wu N, Sun X | Life (Basel) | 2026 | 1 |
| Systemic Neurodegeneration and Brain Aging: Multi-Omics Disintegration, Proteost [PMID:40868276] | Voicu V, Toader C, Șerban M, Covache-Bus | Biomedicines | 2025 | 1 |
| Complement C1q/C3-CR3 signaling pathway mediates abnormal microglial phagocytosi [PMID:38642614] | Han QQ, Shen SY, Liang LF, Chen XR, Yu J | Brain Behav Immun | 2024 | 1 |
| Metabolic orchestration of cell death by AMPK-mediated phosphorylation of RIPK1. [PMID:37384704] | Zhang T, Xu D, Trefts E, Lv M, Inuzuka H | Science | 2023 | 1 |
| Microglia regulation of synaptic plasticity and learning and memory. [PMID:34472455] | Cornell J, Salinas S, Huang HY, Zhou M | Neural Regen Res | 2022 | 1 |
| Complement and microglia mediate early synapse loss in Alzheimer mouse models. [PMID:27033548] | Hong S, Beja-Glasser VF, Nfonoyim BM, Fr | Science | 2016 | 1 |
| Panacis Quinquefolii Radix Polysaccharides Alleviate Depressive-Like Behaviors i [PMID:41914021] | Xie M, Feng L, Li R, Li M, Shen L, Zhang | CNS neuroscience & therapeutic | 2026 | 0 |
| Vaccine-induced antibodies can limit Salmonella infection in the absence of comp [PMID:41738756] | Perez-Toledo M, Aksu-Istil K, Marcial-Ju | mBio | 2026 | 0 |
| The Immuno-Glial Connectome in Alzheimer's Disease: Integrating Central and Peri [PMID:41569436] | Gopalakrishna PK, Che Mohd Nassir CMN, A | Cellular and molecular neurobi | 2026 | 0 |
| Messengers of coagulopathy: complement-carrying extracellular vesicles in SARS-C [PMID:41766448] | Taxiarchis A, Pruner I | Current opinion in hematology | 2026 | 0 |
| Alzheimer's Disease as a Disorder of Neuroimmune Dysregulation. [PMID:41745721] | Aranda-Abreu GE, Rojas-Durán F, Hernánde | Neurology international | 2026 | 0 |
| Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810] | ["Chen Kai", "Li Fuyao", "Zhang Shuwen", | Journal of neuroinflammation | 2025 | 0 |
| The cholesterol 24-hydroxylase CYP46A1 promotes α-synuclein pathology in Parkins [PMID:39964974] | Dai L, Wang J, Meng L, Zhang X, Xiao T, | PLoS biology | 2025 | 0 |
| PDE4 inhibition alleviates HMGB1/C1q/C3-mediated excessive phagocytic pruning of [PMID:39947489] | Zhao Q, Zeng C, Luo F, Xian Z, Wen H, Tu | Brain, behavior, and immunity | 2025 | 0 |
| Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810] | ["Chen Kai", "Li Fuyao", "Zhang Shuwen", | Journal of neuroinflammation | 2025 | 0 |
| LRRK2 kinase-mediated accumulation of lysosome-associated phospho-Rabs in tauopa [PMID:41128923] | Buck SA, Malankhanova T, Strader S, Ma E | Acta neuropathologica | 2025 | 0 |
| Botulinum Neurotoxin Induces Neurotoxic Microglia Mediated by Exogenous Inflamma [PMID:38342616] | Ambrin G, Kang YJ, Van Do K, Lee C, Sing | Advanced science (Weinheim, Ba | 2024 | 0 |
| Development of Injectable Thermosensitive Nanocomposite Hydrogel for Ratiometric [PMID:38456789] | ["Zhu J", "Wei R", "Hu G", "Wang H", "Wa | Small (Weinheim an der Bergstr | 2024 | 0 |
| A molecular switch for neuroprotective astrocyte reactivity. [PMID:38086421] | Cameron EG, Nahmou M, Toth AB, Heo L, Ta | Nature | 2024 | 0 |
| The Role of Complement Dysregulation in Glaucoma. [PMID:38396986] | ["Hoppe C", "Gregory-Ksander M"] | International journal of molec | 2024 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning LIF in their description or question text
Score: 0.780 · neurodegeneration · 2026-04-26
G2019S basal RAB10 phosphorylation elevation may be secondary; true pathogenic driver is amplified stress-response signa
Score: 0.776 · alzheimers · 2026-04-05
## Mechanistic Overview LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Substrate Pools in Disease-Associated M
Score: 0.764 · alzheimers · 2026-04-05
## Mechanistic Overview LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Vulnerability in Disease-Associated Mic
Score: 0.760 · neurodegeneration · 2026-04-25
Oxidative DNA damage hyperactivates PARP1, rapidly consuming NAD+ and collapsing ATP production. Bioenergetic failure im
Score: 0.750 · neurodegeneration · 2026-04-25
The most actionable synthesis is that pathogenicity may depend more on conversion of C1q binding into classical-pathway
Score: 0.750 · neurodegeneration · 2026-04-25
Labile Fe2+ converts H2O2 into hydroxyl radicals, driving phospholipid peroxidation that consumes GSH and disables GPX4-
Score: 0.741 · neurodegeneration · 2026-04-16
**Molecular Mechanism and Rationale** The complement-SASP amplification cascade represents a mechanistic nexus where ce
Score: 0.740 · neurodegeneration · 2026-04-24
A credible refinement is that any true amplification is not universal across cell types, but emerges most strongly in pr
Score: 0.730 · neurodegeneration · 2026-04-26
G2019S specifically hyperactivates LRRK2 when recruited to swelling lysosomes via RAB29, creating pathogenic positive fe
Score: 0.724 · neurodegeneration · 2026-04-13
**Molecular Mechanism and Rationale** The molecular cascade underlying TBK1 loss-of-function-mediated synapse eliminati
Score: 0.720 · neurodegeneration · 2026-04-28
Disease-specific protein aggregates activate microglia via TLRs and NLRP3 inflammasome, driving chronic neuroinflammatio
Score: 0.720 · neurodegeneration · 2026-04-21
## **Molecular Mechanism and Rationale** The pathogenesis of amyotrophic lateral sclerosis (ALS) involves a complex int
Score: 0.710 · neurodegeneration · 2026-04-26
RAB29 functions as a gatekeeper—when lysosomes swell, RAB29-GTP increases, recruits LRRK2, and G2019S hyperphosphorylate
Score: 0.693 · neurodegeneration · 2026-04-21
## Mechanistic Overview Drp1-S616 Phosphorylation Fission Priming Enables t-Bid-Driven MPTP Amplification starts from th
Score: 0.680 · neurodegeneration · 2026-04-21
## Mechanistic Overview Glial Neuroinflammatory Amplification by TDP-43 Pathology starts from the claim that modulating